Background-In patients with heart failure and preserved ejection fraction (HFpEF), atrial fibrillation (AF) may predate, concur with, or develop after HFpEF diagnosis. We sought to define the temporal relationship between AF and HFpEF, to identify factors associated with AF, and to determine the prognostic impact of prevalent and incident AF in HFpEF. Method and Results-From 1983 to 2010, 939 Olmsted County, Minnesota, residents (age, 77±12 years; 61% female) newly diagnosed with HFpEF (EF ≥0.50) were evaluated. Baseline rhythm classification included prior AF (>3 months before HFpEF diagnosis), concurrent AF (±3 months), or sinus rhythm. Incident AF (>3 months after HFpEF diagnosis) and allcause mortality were ascertained through February 2012. Prior AF (29%) and concurrent AF (23%) were associated with older age, higher brain-type natriuretic peptide, and larger left atrial volume index at HFpEF diagnosis compared with sinus rhythm. Of HFpEF patients in sinus rhythm at diagnosis, 32% developed AF over a median follow-up of 3.7 years (interquartile range, 1.5-6.7 years; 69 events per 1000 person-years). Age and diastolic dysfunction were positively and statin use was inversely associated with incident AF. With no AF used as the referent, prior or concurrent AF (combined hazard ratio, 1.3; 95% confidence interval, 1.0-1.6; P=0.03) and incident AF, modeled as a time-dependent covariate (hazard ratio, 2.1; 95% confidence interval, 1.4-3.0; P<0.001), were independently associated with death after adjustment for pertinent covariates. Conclusions-AF occurs in two thirds of HFpEF patients at some point in the natural history and confers a poor prognosis.
T
here is an apparent collusion of 3 major trends: aging of the population, a virtual epidemic of atrial fibrillation (AF), and the emergence of heart failure (HF) with preserved ejection fraction (HFpEF) as the dominant form of HF, almost unique to the elderly. [1] [2] [3] Development of effective therapy for HFpEF has proved challenging, in part because of the heterogeneous and incompletely understood pathophysiological mechanisms that occur in the setting of multiple comorbidities.
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AF is a common comorbidity in HFpEF, reported in 25% to 39% of HFpEF patients, consistent across trial, 4, 5 community, 6 ,7 registry, 8 and hospitalized 9, 10 cohorts. AF may occur in patients destined to develop HFpEF as a result of similar risk factors such as aging and hypertension and may precipitate HF in persons with milder impairment in cardiovascular function as a result of effects on heart rate or atrioventricular synchrony. Alternatively, HFpEF may predispose to AF as a result of chronic left atrial hypertension and atrial remodeling. Thus, AF may represent a consequence of HFpEF progression as occurs in HF with reduced ejection fraction (HFrEF), 11 in which AF is observed in patients with more severe functional impairment and systolic dysfunction. 12 Although previous studies have focused on AF present at the time of recruitment or first HFpEF hospitalization, 5, [13] [14] [15] [16] we examined a large community-based cohort of patients with incident HFpEF who had previous and subsequent ascertainment of AF and vital status. Thus, this cohort provided the unique ability to describe timing of AF occurrence in relation to HFpEF diagnosis. The objective of this study was to determine whether the association of AF with cardiac dysfunction, HF severity, or prognosis differed according to the temporal relationship of AF to HFpEF onset. We hypothesized that regardless of temporal association, the presence of AF is associated with worse cardiac dysfunction, HF severity, and prognosis in HFpEF.
Methods

Study Setting
This population-based cohort study was conducted within Olmsted County, Minnesota, using resources of the Rochester Epidemiology Project as previously described. 6, 17 
Identification of the HFpEF Cohort
Olmsted County residents with a first diagnosis of HF between January 1, 1983, and December 31, 2010 (n=2852), were identified and HF was validated as part of an ongoing Olmsted County HF surveillance study. 6, 18 Patients who underwent echocardiography within 2 months of HF diagnosis with an EF ≥0.5 were determined to have HFpEF and formed the final study cohort. This study was approved by the Mayo Clinic and Olmsted Medical Center Institutional Review boards. Informed consent for examination of medical records (or waiver before 1997) was obtained as appropriate. Prevalent AF was further subdefined as AF occurring prior to (>3 months) or concurrent with (±3 months) HFpEF diagnosis. Patients in sinus rhythm (SR) at the time of HFpEF diagnosis formed the referent population for baseline comparisons and ascertainment of incident AF during follow-up. Incident AF diagnosis was defined by date of first documentation of AF or atrial flutter on ECG or relevant ICD-9-CM code in the medical record >3 months after HFpEF diagnosis, during any hospitalization, or during any outpatient visit. AF-related diagnostic codes were included because 12-lead ECG documentation alone has previously been reported to miss up to 10% of cases. 19 A random sample of 183 positively coded records were reviewed, and ECG or other documentation (rhythm strip or Holter monitor) of AF confirmed AF in all cases.
AF Ascertainment
Data Collection
Patient demographics, clinical diagnoses, laboratory results, and CHADS 2 and CHA 2 DS 2 -VASc scores 20 were electronically abstracted from medical records (see Methods in the online-only Data Supplement). Echocardiographic data, including EF, left ventricular dimensions, diastolic function, pulmonary artery pressure, left atrial volume index (LAVI), and valvular disease within 2 months of HFpEF diagnosis, were obtained from the Mayo Clinic echocardiographic database.
Ascertainment of Vital Status
Vital status was determined through February 29, 2012 , via Rochester Epidemiology Project procedures as previously described. 
Statistical Analysis
Group data are presented as frequencies, mean±SD, or median and interquartile range as appropriate. Because estimated glomerular filtration rate, brain-type natriuretic peptide, and thyroid-stimulating hormone distributions were skewed, values were log-transformed for analysis. Across-group comparisons were made with the Pearson χ 2 test for categorical variables and 1-way ANOVA or Kruskal-Wallis test for continuous variables. Pairwise comparisons across groups were subject to Bonferroni correction for multiple comparisons. Cox proportional hazards regression was used to identify patient characteristics associated with incident AF. Unadjusted and ageand sex-adjusted Cox models were explored, with additional multivariable models adjusting for pertinent clinical baseline variables. Significant correlations and interactions (P<0.05) were assessed and accounted for.
Overall survival was estimated with the Kaplan-Meier method. Between-group survival was compared by the log-rank test. Cox proportional hazards regression was used to examine the association between all-cause death and AF status, controlling for pertinent covariates. Incident AF was modeled as a time-dependent covariate. All P values were 2 tailed; values of P<0.05 were considered the threshold for statistical significance. Analyses were performed with JMP version 9.0 (SAS Institute, Cary, NC) and R version 2.14.1 (The R Foundation for Statistical Computing).
Results
Population Characteristics
Over the study period, 2852 Olmsted County residents had a new HF diagnosis. In 872 patients, echocardiographic confirmation of EF was unavailable. These patients were older and had more chronic obstructive pulmonary disease but were otherwise comparable to patients with confirmed EFs ( Figure 1 ). Among patients with prior AF, the median duration of AF was 5.1 years (interquartile range, 2.4-10.0 years). Prevalent AF was defined as prior and concurrent combined and varied but did not appreciably increase over the study duration (1983-1990, 56%; 1991-2000, 45%; 2001-2010, 56%) .
Compared with patients in SR, HFpEF patients with prior or concurrent AF were older, had higher brain-type natriuretic peptide and LAVI, had shorter deceleration times, and tended to have higher E/e′ (Table 1) . Patients with concurrent AF had higher heart rates than patients with prior AF or SR, lower blood pressure and diabetes mellitus prevalence than HFpEF patients in SR, and lower LAVI and statin use than patients with prior AF. Patients with prior AF had more cerebrovascular disease than patients in SR or with concurrent AF. Importantly, standard HF medications, EF, left ventricular size, and pulmonary pressures were similar regardless of AF status.
Incidence and Risk Factors for AF in HFpEF
Over a median follow-up of 3.7 years, 142 patients (31.6%) in SR at HFpEF diagnosis were subsequently diagnosed with AF, giving an unadjusted incidence of 69 AF events per 1000 person-years. The median time to AF development was 3.1 years (interquartile range, 1.2-5.0 years; Figure 2 ). No significant secular trend in AF incidence was observed over the study duration (time period: unadjusted P=0.28; age-and sexadjusted P=0.18).
HFpEF patients who developed AF had less severe symptoms and lower rates of statin use at HF diagnosis than patients who did not; otherwise, they were similar with respect to baseline clinical and echocardiographic characteristics (Table 2 ). Univariable associations with incident AF included older age, hypertension, lower estimated glomerular filtration rate, larger LAVI, and higher filling pressures (estimated by E/e′; Table 3) . 20 LAVI and E/e′ were moderately correlated with each other (Spearman ρ=0.3; P=0.0005). In multivariable models, higher E/e′ remained associated with Table II in the online-only Data Supplement). Statin use was associated with a lower incidence of AF before and after adjustment for age and sex (Table 3) , 20 pertinent clinical variables (hazard ratio, 0.60; 95% confidence interval, 0.38-0.92; P=0.02; Table II in the online-only Data Supplement), and low-density lipoprotein levels within 1 year of HFpEF diagnosis (hazard ratio, 0.54; 95% confidence interval, 0.32-0.89; P=0.02; Table III in the online-only Data Supplement). The CHADS 2 and CHA 2 DS 2 -VASc scores were also associated with incident AF (Table 3) . 20 
Impact of AF on Survival in HFpEF
Survival data were available for all patients in this study. The median follow-up was 4.3 years (interquartile range, 1.9-7.2 years) or 3998 person-years after HFpEF diagnosis. There were 684 deaths overall (72.8% of the study population). Survival at 2 years was lower in subjects with prevalent AF compared with SR at HFpEF diagnosis (73.2 versus 79.8%; P=0.02; Figure 3) . Compared with HFpEF patients without prevalent or incident AF, prevalent AF was associated with reduced survival even after adjustment for age, sex, and pertinent clinical variables (Table 4) . When stratified by AF group, prior AF was associated with reduced age-and sex-adjusted survival (hazard ratio for mortality, 1.40; 95% confidence interval, 1.16-1.70; P<0.0006), while concurrent AF demonstrated a trend toward reduced age-and sex-adjusted survival (hazard ratio, 1.18; 95% confidence interval, 0.96-1.45; P=0.11) compared with patients with no AF. The independent relationship between prior AF and mortality persisted after adjustment for pertinent covariates (Table IV in the onlineonly Data Supplement). Compared with HFpEF patients without prevalent or incident AF, incident AF was also independently associated with reduced survival after adjustment for pertinent covariates (Table 4) . No sex-based differences were observed in AF incidence or HFpEF survival in this study.
Discussion
In this large, population-based cohort study, more than two thirds of HFpEF patients had AF prior to, concurrent with, or subsequent to HFpEF diagnosis, underscoring the interplay of these 2 conditions. At HFpEF diagnosis, patients with prevalent (prior or concurrent) AF were older and had larger atria, worse diastolic dysfunction, and higher brain-type natriuretic peptide levels than those in SR, consistent with more advanced HF. Development of incident AF was associated with older age, hypertension, renal dysfunction, left atrial dilatation, and diastolic dysfunction at HF diagnosis, but fewer patients treated with statins at HF diagnosis developed AF over time. Scores predictive of thromboembolic risk in AF were also associated with incident AF in HFpEF patients. Importantly, both prevalent AF and incident AF were associated with worse survival in HFpEF even after adjustment for potential confounders. These data suggest that AF may be a marker and potentially a mediator of increased mortality in HFpEF independent of other known risk factors.
Prevalence of AF in HFpEF
AF was present in >50% of our community-based HFpEF patients at HF diagnosis, which greatly exceeds previous reported estimates from hospitalized 8, 9 or clinical trial cohorts even with lower EF cutoffs 4,5 and previous population-based studies. 6, 7, 21 Because there was no increase in AF prevalence over the study period, these data suggest that AF may be more prevalent among HFpEF patients than previously appreciated. Diagnosis of AF can incorporate a number of subtypes, including paroxysmal AF, and a persistent or chronic form. Our inclusion of any prior diagnosis of AF, specifically to include rigorous paroxysmal AF ascertainment from medical records, may account for a higher prevalence compared with other studies determining AF status in HFpEF. In the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity in Patients With Preserved LeftVentricular Ejection Fraction (CHARM-Preserved) trial, patients with an ECG demonstrating SR but with a history of AF were nonetheless categorized as no AF. 22 However, progression of paroxysmal AF to persistent and then chronic AF is well recognized, 23 and the clinical associations and adverse prognostic implications of prevalent AF as classified here support its clinical relevance. AF and HFpEF share a number of common risk factors. In this study, patients with prevalent AF were older with more cerebrovascular disease (prior AF group) but otherwise had a clinical profile similar to that of HFpEF patients without AF at HF diagnosis. Brain-type natriuretic peptide was higher among patients with prevalent AF, although symptom severity (New York Heart Association class) at presentation was similar between groups. The graded association between LAVI and duration of AF, that is, larger in patients with prior than concurrent AF and smallest in HFpEF patients with no AF, supports a link between left atrial remodeling in HFpEF and AF development. Several clinical studies have reported that diastolic dysfunction is a risk factor for incident AF in the general population. 24, 25 Among markers of diastolic function, we also found that a shorter E-wave deceleration time was associated with prevalent AF in HFpEF.
Incidence of AF in HFpEF
The incidence rate of AF in this study was 69 cases per 1000 person-years. By comparison, AF incidence rates reported in the general population range from 3 to 6 cases per 1000 person-years 26, 27 to 28.3 per 1000 person-years in US Medicare beneficiaries ≥65 years of age. 28 In keeping with the notion that structural heart disease may promote atrial remodeling and maintenance of AF, a higher observed incidence among HFpEF patients is expected here. Interestingly, however, the incidence rate also exceeds that reported among Framingham HFrEF patients (54 cases per 1000 person-years; mean age, 73±11 years) 29 and after myocardial infarction in Olmsted County subjects (42 cases per 1000 person-years; mean age, 68±15 years) 30 despite a mean age comparable to that of HFpEF patients presenting in SR. This is noteworthy from a public health perspective because recent studies in clinical trial cohorts have suggested that prevalent AF imparts a greater relative risk of cardiovascular death or hospitalization for worsening HF in HFpEF patients compared to those with HFrEF. 5, 22 An incidence rate for AF in HFpEF patients in the community has not been reported previously. In the CHARMPreserved trial, only 4.9% of the HFpEF (EF ≥0.40) cohort in SR at recruitment developed AF by the end of the study (median follow-up, 37.7 months) compared with a crude incidence of 31.6% over 44 months in the present cohort. The CHARM cohort was younger at baseline (mean age, 66.4±11.1 years) and healthy enough to enter a clinical trial. However, CHARM patients had prevalent rather than incident HFpEF and were required to have had a previous cardiovascular hospitalization for inclusion in the trial. 22 It is likely that our examination of the broader spectrum of HFpEF patients in the community setting accounts for the differences in AF incidence, further underscoring the difference between clinical trial and community cohorts.
Not unexpectedly, we found that increasing age and degree of diastolic dysfunction (E/e′) predicted incident AF in HFpEF patients presenting in SR, as has been observed in other clinical contexts. 24, 27 Our data confirm that these Statin use displayed a significant and age-independent negative association with incident AF. A similar association has been shown in patients with coronary artery disease, 31, 32 after cardiac surgery, 33 and between statin use and recurrent AF in patients with a history of AF. 34 However, the current data are the first to report an (inverse) association between statin use and AF incidence in HFpEF, which persists after multivariable adjustment, including low-density lipoprotein levels. An antiarrhythmic effect of statins has been attributed to anti-inflammatory properties, 35 reduction of oxidative stress, 36 or modulation of the autonomic nervous system. 37 Although the Controlled Rosuvastatin in Multinational Trial in Heart Failure (CORONA) did not demonstrate a reduction in mortality with statin use in HFrEF, 38 a reduction in cardiovascular hospitalizations was observed that may be related to the effects of statin use on AF incidence. An ancillary analysis of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure (GISSI-HF) population (mixed HF type) also reported that rosuvastatin therapy was correlated with a decreased incidence of AF compared with placebo. 39 Because no therapy has yet been shown to improve outcomes or to reduce symptom burden in HFpEF, this novel finding warrants further investigation.
Association Between AF and Survival in HFpEF
Although previous studies have described the prognosis of patients with HFpEF and AF, most, if not all, concentrated on prevalent AF 40 and largely compared outcomes with HFrEF patients rather than HFpEF patients without AF, as recently reviewed. 41 Importantly, we have demonstrated that incident AF after HFpEF diagnosis confers an independent and greater risk of death than either prevalent AF (prior or concurrent) or no AF among HFpEF patients in the community. Because incident AF was not incorporated into most previous studies, the prognostic implications of AF in HFpEF may have been underestimated. Indeed, our findings are in agreement with a recent analysis of the Cardiovascular Research Network PRESERVE Study in which incident AF was associated with a similar, albeit slightly lower, risk of all-cause death in HFpEF patients. 42 A less stringent definition of incident AF (AF occurring any time after recruitment) and shorter median follow-up duration (1.8 versus 3.7 years here) may explain the lower risk observed. Nevertheless, whether incident AF represents a marker and/or mediator of HFpEF progression remains unknown and difficult to confirm in an epidemiological study. Our multivariable analysis suggests that the greater mortality more likely attributes to AF than other currently recognized (and adjusted for) prognostic factors, including age, hypertension, and left ventricular diastolic function. Because AF increases the rate of thromboembolic events and may worsen global cardiac performance and thus contribute to neurohumoral activation, prevention of AF may ameliorate the adverse outcomes associated with its presence. Although the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) 43 and the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial 44 failed to demonstrate an overall survival advantage associated with restoring and maintaining SR in a general AF or HFrEF population, respectively, patients with HFpEF were excluded from the AF-CHF trial; thus, a rhythm control strategy has not been tested in a dedicated HFpEF population.
Notably, this study also delineates an independent risk of death associated with concurrent AF in univariable analysis, although only a trend toward an association (P=0.11) after adjustment for age and sex (Table IV in the online-only Data Supplement). In these patients, the chronology of events and permanence of AF are less clear. Additionally, fewer patients with concurrent AF had a history of myocardial infarction compared with patients with prior AF, and fewer had diabetes mellitus compared with SR patients at HFpEF diagnosis. We speculate that this group represents a combination of patients with preexisting but unrecognized AF and patients with less severe cardiovascular dysfunction in whom new-onset AF and its adverse hemodynamic sequelae may have been the triggering mechanism for emergence of HF.
Limitations
Rhythm classification depended on clinical detection and documentation of AF in the medical record. Patients with asymptomatic AF may therefore be underrepresented in AF groups, although any resulting survival bias would more likely underestimate AF incidence and AF-related risk. A portion of patients for whom echocardiographic EF data were unavailable may have been more likely to have HFpEF and AF. As a group, patients without EF assessment were older and had a higher prevalence of chronic obstructive pulmonary disease (Table I in the online-only Data Supplement). Thus, the impact of AF on outcomes in HFpEF may have been underestimated as a result of the exclusion of this particularly high-risk subgroup. Observed associations with incident AF will generalize to HFpEF cases surviving beyond 3 months, as per the definition used. Detailed data on treatment regimens, adequacy of rate control and anticoagulation for AF patients, and cause of death were not ascertained. Similarly, in mortality analyses, information on covariates besides rhythm was unavailable to update over time, including subsequent antiarrhythmic use, and may confound the risk of death observed. The population of Olmsted County is mainly white. Because the prevalence 45 and incidence 46 of AF are higher 
Conclusions
In this large population-based cohort of incident HFpEF, 66% of patients had AF prior to, concurrent with, or subsequent to HFpEF diagnosis. Moreover, prevalent AF and incident AF were independently associated with increased mortality. In the absence of proven treatment strategies for HFpEF, further studies are required to determine whether AF represents a marker of HFpEF progression and/or a therapeutic target. LAVI and E/e' were moderately correlated with one another (Spearman's ρ 0.3, p=0.0005), therefore not included in the same model.
Correction
Supplemental
E/e', ratio of early diastolic mitral inflow velocity (pulsed wave Doppler) to early diastolic (medial) mitral annular velocity (tissue Doppler); eGFR, estimated glomerular filtration rate; LAVI, left atrial volume index. 
